Monday, March 27, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

Scientific Services for FLUIGIV Pandemic Flu Countermeasure

by Global Biodefense Staff
August 29, 2014

The Food and Drug Administration, Center for Biologics Evaluation for Research (CBER), Laboratory of Plasma Derivatives has a requirement for research services for post-exposure treatment of pandemic influenza with FLUIGIV.

FDA has studied FLUIGIV in vitro, confirming that the product has anti-influenza antibody neutralizing activity 16-fold greater than that of comparator lots by hem-agglutination inhibition. FDA has also completed a Phase I study of tolerability and pharmacokinetics to assure that FLUIGIV can be given safely to ferrets.  FDA modified the original protocol to enable human-level doses to be tolerated by ferrets, and determining the maximum serum concentration (Cmax) of subcutaneously delivered FLUIGIV to occur 2 days post infusion.

A phase II study of FLUIGIV for prevention of pdm09H1N1 disease in ferrets is complete and respiratory tissue viral burdens are pending.  The purpose of this contract is to test FLUIGIV given after infection, to determine its effectiveness as a treatment.

Preclinical studies in ferrets will best determine the potential of a FLUIGIV to be effective in the setting of a pandemic outbreak.  Efficacy demonstration has broad implications for pandemic preparedness, which then can be improved by prompt collection and manufacture of FLUIGIV for disease prevention in high-risk individuals, and treatment of antibiotic-resistant cases during a pandemic.

The contractor will provide support for phlebotomy, processing sera, collection of nasal washes, tissue collection and homogenization (for viral load and/or antibody measurements), and performance of TCID50 assays to assess tissue viral loads.

The period of performance is six months after receipt of order (ARO). Details are available under Solicitation Number: FDA-SOL-1135604.

Tags: InfluenzaPandemic

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC